Comparative effectiveness of treatment with the first TNF antagonist in monotherapy, the first TNF antagonist plus one conventional synthetic disease-modifying antirheumatic drug, and the first TNF antagonist plus two or more conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis

BACKGROUND: Rheumatoid arthritis (RA) patients are treated with a mean of 3–4 conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) with or without glucocorticoids (GCs), before the first biologic prescription. The main reasons for change are inefficacy in 30–40 % of patients, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Hernández-Cruz, Blanca, Márquez-Saavedra, Esther, Caliz-Caliz, Rafael, Navarro-Sarabia, Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5100281/
https://www.ncbi.nlm.nih.gov/pubmed/27821150
http://dx.doi.org/10.1186/s13075-016-1137-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5100281/
https://www.ncbi.nlm.nih.gov/pubmed/27821150
http://dx.doi.org/10.1186/s13075-016-1137-4

Ejemplares similares